Sign in
Taking peoplePhase 2

A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents With Advanced NUT Cancer

Key facts

Who runs it
Zhejiang Wenda Pharma Technology LTD.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
68 people, planned
Started
25 Apr 2024
Expected to end
30 Aug 2027
Type of study
Interventional
Treatments tested
  • NHWD-870 HCl
Record updated
16 November 2026

Who can take part

Age
12 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • A written informed consent signed
  • Subjects must sign and date IEC-approved written informed consent in accordance with the guidelines of the competent authorities and research institutions. Informed consent had to be obtained before any protocol-related procedure that was not part of a participant's routine care was performed
  • Participants must be willing and able to comply with the scheduled visits, treatment protocols, laboratory tests, and other requirements of the study
  • If the subjects were under 18, the participants and their legal guardian authorization signed agreement
  • Both sexes, the first part (adult group) was ≥18 years old and ≤75 years old, the second part (adolescent group) was ≥12 years old and <18 years old
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2
  • The expected survival period for 3 months or more
  • The histopathological (histopathological diagnosis was the first time according to the tumor tissue pathologic specimens before three years, if more than 3 years should be confirmed in the center of the study to do a biopsy. If, in the investigator's judgment, a biopsy might increase a subject's risk, archival tumor tissue samples up to 3 years old could be collected after discussion with the sponsor) were diagnosed as midline (NUT) cancer by, but not limited to:
  • Determination of ectopic NUT protein expression by IHC
  • Detection of NUT gene translocations by fluorescence in situ hybridization (FISH)
  • Detection of NUT gene translocations (e.g. BRD3/4 mutation or ≥ 2-fold amplification) by DNA/RNA sequencing

Who cannot take part

  • Prior treatment with a BET inhibitor
  • Patients with clinically significant bleeding symptoms or clear bleeding tendency within 3 months before enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, etc
  • 3 years before into the group suffering from other malignant tumors, with the exception of removal of cure of basal cell carcinoma, orthotopic bladder cancer or cervical carcinoma in situ
  • The researchers believe the subjects is the need for systemic anti-infection treatment of active infection
  • Imaging shows that the tumor has invaded important blood vessels or the investigators judge that the tumor is likely to invade important blood vessels and cause fatal hemorrhage during the follow-up study

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Advanced solid tumor

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, open-label, single-arm, phase II study to evaluate the efficacy, safety, and pharmacokinetics of NHWD-870 HCl in adults and adolescents with advanced NUT cancer.

The group in the trial

  • Adult:NHWD-870 HCl 2mg ; Adolescent:NHWD-870 HCl 1.5mg/2mgTreatment being tested

    Take a fixed dose of NHWD-870 HCl tablets orally.

    Treatment: NHWD-870 HCl

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06527300, who can take part
Record updated
16 November 2026